PLAGL2 and central nervous system embryonal neoplasm: To account for all three subtypes in the nomenclature, we propose to rename ET, PLAGL to ET, PLAG—CNS embryonal tumor with PLAG family gene alteration—and, especially with regards to the differences in survival and between the recommended treatments [10], advocate for an additional specification of the respective subtype, i.e. PLAG1-fused, PLAGL1-amplified, or PLAGL2-amplified as proposed in Fig. 6.